On surmounting the barriers to HPV vaccination: we can do better

References

• Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(5):F12–F23.
   PubMed Web of Science ®Google Scholar
• Lee LY, Garland SM. Human papillomavirus vaccination: the population impact. F1000Res. 2017;6:866.
   PubMedGoogle Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805–814.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73.
   PubMed Web of Science ®Google Scholar
• Organization WH. Media centre. Human papillomavirus (HPV) and cervical cancer. Geneva: WHO; 2015.
   Google Scholar
• Somers GR, Tabrizi SN, Borg AJ, et al. Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatr Pathol Lab Med. 1997;17:53–64.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–110.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
   PubMed Web of Science ®Google Scholar
• Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–723.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older–United States, 2013. MMWR Suppl. 2013;62:1.
   Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–24.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705–1708.
   PubMedGoogle Scholar
• Pediatrics AAO. HPV vaccine implementation guidance. 2017 [cited 2017 Jul 13]. Available from: https://www.aap.org/en-us/Documents/immunization_hpvimplementationguidance.pdf
   Google Scholar
• Gynecologists TACoOa. Committee opinion 704: human papillomavirus Vaccination. Obstet Gynecol. 2017;129(6):e173–e178.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years-United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:874–882.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013-United States. MMWR Morb Mortal Wkly Rep. 2013;62:591–595.
   PubMed Web of Science ®Google Scholar
• Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211.
   Web of Science ®Google Scholar
• Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215.
   PubMed Web of Science ®Google Scholar
• Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983; 51:390–395.
   PubMed Web of Science ®Google Scholar
• Rogers RW. A protection motivation theory of fear appeals and attitude change1. J Psychol. 1975;91:93–114.
   PubMed Web of Science ®Google Scholar
• Weinstein ND, Sandman PM. A model of the precaution adoption process: evidence from home radon testing. Health Psychol. 1992;11:170–180.
   PubMed Web of Science ®Google Scholar
• Weinstein ND. The precaution adoption process. Health Psychol. 1988;7:355–386.
   PubMed Web of Science ®Google Scholar
• Harrison JA, Mullen PD, Green LW. A meta-analysis of studies of the Health Belief Model with adults. Health Educ Res. 1992;7:107–116.
   PubMed Web of Science ®Google Scholar
• Gerend MA, Shepherd MA, Shepherd JE. The multidimensional nature of perceived barriers: global versus practical barriers to HPV vaccination. Health Psychol. 2013;32:361–369.
   PubMed Web of Science ®Google Scholar
• Dorell CG, Yankey D, Santibanez TA, et al. Human papillomavirus vaccination series initiation and completion, 2008–2009. Pediatrics. 2011;128:830–839.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, Moss JL, McRee AL, et al. Do correlates of HPV vaccine initiation differ between adolescent boys and girls? Vaccine. 2012;30:5928–5934.
   PubMed Web of Science ®Google Scholar
• Kester LM, Zimet GD, Fortenberry JD, et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J. 2013;17:879–885.
   PubMed Web of Science ®Google Scholar
• Hamlish T, Clarke L, Alexander KA. Barriers to HPV immunization for African American adolescent females. Vaccine. 2012;30:6472–6476.
   PubMed Web of Science ®Google Scholar
• Litton AG, Desmond RA, Gilliland J, et al. Factors associated with intention to vaccinate a daughter against HPV: a statewide survey in Alabama. J Pediatr Adolesc Gynecol. 2011;24:166–171.
   PubMed Web of Science ®Google Scholar
• Holman DM, Benard V, Roland KB, et al. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2014;168:76–82.
   PubMed Web of Science ®Google Scholar
• Bastani R, Glenn BA, Tsui J, et al. Understanding suboptimal human papillomavirus vaccine uptake among ethnic minority girls. Cancer Epidemiol Biomarkers Prev. 2011;20:1463–1472.
   PubMed Web of Science ®Google Scholar
• Stokley S, Cohn A, Dorell C, et al. Adolescent vaccination-coverage levels in the United States: 2006–2009. Pediatrics. 2011;128:1078–1086.
   PubMed Web of Science ®Google Scholar
• Kepka DL, Ulrich AK, Coronado GD. Low knowledge of the three-dose HPV vaccine series among mothers of rural Hispanic adolescents. J Health Care Poor Underserved. 2012;23:626–635.
   PubMed Web of Science ®Google Scholar
• Oldach BR, Katz ML. Ohio appalachia public health department personnel: human papillomavirus (HPV) vaccine availability, and acceptance and concerns among parents of male and female adolescents. J Community Health. 2012;37:1157–1163.
   PubMed Web of Science ®Google Scholar
• Wilson R, Brown DR, Boothe MA, et al. Knowledge and acceptability of the HPV vaccine among ethnically diverse black women. J Immigrant Minority Health. 2013;15:747–757.
   PubMed Web of Science ®Google Scholar
• Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics. 2010;126:425–433.
   PubMed Web of Science ®Google Scholar
• Dorell C, Yankey D, Strasser S. Parent-reported reasons for nonreceipt of recommended adolescent vaccinations, national immunization survey: teen, 2009. Clin Pediatr (Phila). 2011;50:1116–1124.
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Stahlman S, Walker S, et al. Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community. Vaccine. 2012;30:4511–4516.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Clark JA. What affects human papillomavirus vaccination rates? A qualitative analysis of providers’ perceptions. Womens Health Issues. 2012;22:e379–e386.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Clark JA. Providers’ attitudes toward human papillomavirus vaccination in young men: challenges for implementation of 2011 recommendations. Am J Mens Health. 2012;6:320–323.
   PubMed Web of Science ®Google Scholar
• Quinn GP, Murphy D, Malo TL, et al. A national survey about human papillomavirus vaccination: what we didn’t ask, but physicians wanted us to know. J Pediatr Adolesc Gynecol. 2012;25:254–258.
   PubMed Web of Science ®Google Scholar
• Kempe A, Daley MF, McCauley MM, et al. Prevalence of parental concerns about childhood vaccines: the experience of primary care physicians. Am J Prev Med. 2011;40:548–555.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630–632.
   PubMedGoogle Scholar
• Stupiansky NW, Alexander AB, Zimet GD. Human papillomavirus vaccine and men: what are the obstacles and challenges? Curr Opin Infect Dis. 2012;25:86–91.
   PubMed Web of Science ®Google Scholar
• Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynecol Oncol. 2010;117:S26–S31.
   PubMed Web of Science ®Google Scholar
• Liddon N, Hood J, Wynn BA, et al. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health. 2010;46:113–123.
   PubMed Web of Science ®Google Scholar
• Donahue KL, Stupiansky NW, Alexander AB, et al. Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. Vaccine. 2014;32:3883–3885.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:1018–1023.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years–United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117–1123.
   PubMedGoogle Scholar
• Reiter PL, McRee AL, Gottlieb SL, et al. HPV vaccine for adolescent males: acceptability to parents post-vaccine licensure. Vaccine. 2010;28:6292–6297.
   PubMed Web of Science ®Google Scholar
• McRee AL, Reiter PL, Chantala K, et al. Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev. 2010;19:1937–1944.
   PubMed Web of Science ®Google Scholar
• Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845–852.
   PubMed Web of Science ®Google Scholar
• Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007;85:719–726.
   PubMed Web of Science ®Google Scholar
• Velan B, Yadgar Y. On the implications of desexualizing vaccines against sexually transmitted diseases: health policy challenges in a multicultural society. Isr J Health Policy Res. 2017;6:30.
   PubMed Web of Science ®Google Scholar
• Velan B. Acceptance on the move: public reaction to shifting vaccination realities. Hum Vaccin. 2011;7:1261–1270.
   PubMed Web of Science ®Google Scholar
• Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–125.
   PubMed Web of Science ®Google Scholar
• Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63:519–527.
   PubMed Web of Science ®Google Scholar
• Ferris DG, Samakoses R, Block SL, et al. 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140:e20163947.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygard M, Dillner J, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2017.
   PubMed Web of Science ®Google Scholar
• Donahue KL, Hendrix KS, Sturm LA, et al. Human papillomavirus vaccine initiation among 9–13-year-olds in the United States. Prev Med Rep. 2015;2:892–898.
   PubMedGoogle Scholar
• Zimet GD, Rosberger Z, Fisher WA, et al. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med. 2013;57:414–418.
   PubMed Web of Science ®Google Scholar
• Zimet GD, Shew ML, Kahn JA. Appropriate use of cervical cancer vaccine. Annu Rev Med. 2008;59:223–236.
   PubMed Web of Science ®Google Scholar
• Ogilvie G, Anderson M, Marra F, et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 2010;7:e1000270.
   PubMed Web of Science ®Google Scholar
• Schuler CL, Reiter PL, Smith JS, et al. Human papillomavirus vaccine and behavioural disinhibition. Sex Transm Infect. 2011;87:349–353.
   PubMed Web of Science ®Google Scholar
• Bednarczyk RA, Davis R, Ault K, et al. Sexual activity-related outcomes after human papillomavirus vaccination of 11to 12-year-olds. Pediatrics. 2012;130:798–805.
   PubMed Web of Science ®Google Scholar
• Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine. 2012;30:5496–5499.
   PubMed Web of Science ®Google Scholar
• Forster AS, Marlow LA, Stephenson J, et al. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. Vaccine. 2012;30:4939–4944.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Xu J, Zimet GD, et al. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health. 2012;50:464–470.
   PubMed Web of Science ®Google Scholar
• Mullins TL, Zimet GD, Rosenthal SL, et al. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med. 2012;166:82–88.
   PubMedGoogle Scholar
• Smith LM, Kaufman JS, Strumpf EC, et al. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. CMAJ. 2015;187:E74–E81.
   PubMed Web of Science ®Google Scholar
• Sebelius K. Report to congress on preventive services and obesity-related services available to Medicaid enrollees; Washington (DC): Health and Human Services; 2014.
   Google Scholar
• VFC-ACIP vaccine resolutions. 2016 [cited 2017 Jul 13]. Available from: https://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/2016-10-2-hpv.pdf
   Google Scholar
• The HPV vaccine: background, coverage & benefits. Washington (DC): Association of maternal and child health programs; 2007.
   Google Scholar
• Berenson AB, Rahman M. Gender differences among low income women in their intent to vaccinate their sons and daughters against human papillomavirus infection. J Pediatr Adolesc Gynecol. 2012;25:218–220.
   PubMed Web of Science ®Google Scholar
• Gowda C, Dempsey AF. Medicaid reimbursement and the uptake of adolescent vaccines. Vaccine. 2012;30:1682–1689.
   PubMed Web of Science ®Google Scholar
• Wisk LE, Allchin A, Witt WP. Disparities in human papillomavirus vaccine awareness among US parents of preadolescents and adolescents. Sex Transm Dis. 2014;41:117–122.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113:3036–3046.
   PubMed Web of Science ®Google Scholar
• Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health. 2008;43:S52–S60.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2017; JCO-2017.
   Web of Science ®Google Scholar
• Hughes J, Cates JR, Liddon N, et al. Disparities in how parents are learning about the human papillomavirus vaccine. Cancer Epidemiol Biomarkers Prev. 2009;18:363–372.
   PubMed Web of Science ®Google Scholar
• Cates JR, Shafer A, Carpentier FD, et al. How parents hear about human papillomavirus vaccine: implications for uptake. J Adolesc Health. 2010;47:305–308.
   PubMed Web of Science ®Google Scholar
• Cui Y, Baldwin SB, Wiley DJ, et al. Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. Am J Prev Med. 2010;39:559–563.
   PubMed Web of Science ®Google Scholar
• Garner EI. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev. 2003;12:242s–247s.
   PubMed Web of Science ®Google Scholar
• Reiter PL, Stubbs B, Panozzo CA, et al. HPV and HPV vaccine education intervention: effects on parents, healthcare staff, and school staff. Cancer Epidemiol Biomarkers Prev. 2011;20:2354–2361.
   PubMed Web of Science ®Google Scholar
• Darden PM, Thompson DM, Roberts JR, et al. Reasons for not vaccinating adolescents: national immunization survey of teens, 2008–2010. Pediatrics. 2013;131:645–651.
   PubMed Web of Science ®Google Scholar
• Laz TH, Rahman M, Berenson AB. An update on human papillomavirus vaccine uptake among 11–17 year old girls in the United States: national health interview survey, 2010. Vaccine. 2012;30:3534–3540.
   PubMed Web of Science ®Google Scholar
• De Vincenzo R, Conte C, Ricci C, et al. Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health. 2014;6:999–1010.
   PubMedGoogle Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10:2147–2162.
   PubMed Web of Science ®Google Scholar
• Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26:6844–6851.
   PubMed Web of Science ®Google Scholar
• Miranda S, Chaignot C, Collin C, et al. Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2million young girls in France. Vaccine. 2017;35:4761–4768.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–2159.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1–30.
   PubMed Web of Science ®Google Scholar
• Whelan AM. Lowering the age of consent: pushing back against the anti-vaccine movement. J Law Med Ethics. 2016;44:462–473.
   PubMed Web of Science ®Google Scholar
• Suhay E, Druckman JN, Fowler EF, et al. The content and effect of politicized health controversies. ANN Am Acad Pol Soc Sci. 2015;658:155–171.
   Web of Science ®Google Scholar
• Shelton RC, Snavely AC, De Jesus M, et al. HPV vaccine decision-making and acceptance: does religion play a role? J Relig Health. 2013;52:1120–1130.
   PubMed Web of Science ®Google Scholar
• Kulig JC, Meyer CJ, Hill SA, et al. Refusals and delay of immunization within southwest Alberta. Understanding alternative beliefs and religious perspectives. Can J Public Health. 2002;93:109–112.
   PubMed Web of Science ®Google Scholar
• Salmon DA, Sapsin JW, Teret S, et al. Public health and the politics of school immunization requirements. Am J Public Health. 2005;95:778–783.
   PubMed Web of Science ®Google Scholar
• Etkind P, Lett SM, Macdonald PD, et al. Pertussis outbreaks in groups claiming religious exemptions to vaccinations. Am J Dis Child. 1992;146:173–176.
   PubMedGoogle Scholar
• Kennedy AM, Gust DA. Measles outbreak associated with a church congregation: a study of immunization attitudes of congregation members. Public Health Rep. 2008;123:126–134.
   PubMed Web of Science ®Google Scholar
• Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40:108–115.
   PubMed Web of Science ®Google Scholar
• Marlow LA, Wardle J, Forster AS, et al. Ethnic differences in human papillomavirus awareness and vaccine acceptability. J Epidemiol Community Health. 2009;63:1010–1015.
   PubMed Web of Science ®Google Scholar
• Marlow LA, Waller J, Evans RE, et al. Predictors of interest in HPV vaccination: a study of British adolescents. Vaccine. 2009;27:2483–2488.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13–17 years–United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:671–677.
   PubMedGoogle Scholar
• Widdice LE, Bernstein DI, Leonard AC, et al. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics. 2011;127:77–84.
   PubMed Web of Science ®Google Scholar
• Schluterman NH, Terplan M, Lydecker AD, et al. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine. 2011;29:3767–3772.
   PubMed Web of Science ®Google Scholar
• Gold R, Naleway AL, Jenkins LL, et al. Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med. 2011;52:456–458.
   PubMed Web of Science ®Google Scholar
• Chou B, Krill LS, Horton BB, et al. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol. 2011;118:14–20.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Mehta NR, Hadler JL. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Prev Med. 2011;41:428–433.
   PubMed Web of Science ®Google Scholar
• Boscoe FP, Johnson CJ, Sherman RL, et al. The relationship between area poverty rate and site-specific cancer incidence in the United States. Cancer. 2014;120:2191–2198.
   PubMed Web of Science ®Google Scholar
• Henry KA, Stroup AM, Warner EL, et al. Geographic factors and human papillomavirus (HPV) vaccination initiation among adolescent girls in the United States. Cancer Epidemiol Biomarkers Prev. 2016; 25:309–317.
   PubMed Web of Science ®Google Scholar
• Merkin SS, Stevenson L, Powe N. Geographic socioeconomic status, race, and advanced-stage breast cancer in New York City. Am J Public Health. 2002;92:64–70.
   PubMed Web of Science ®Google Scholar
• Warner ET, Gomez SL. Impact of neighborhood racial composition and metropolitan residential segregation on disparities in breast cancer stage at diagnosis and survival between black and white women in California. J Community Health. 2010;35:398–408.
   PubMed Web of Science ®Google Scholar
• Shariff-Marco S, Yang J, John EM, et al. Impact of neighborhood and individual socioeconomic status on survival after breast cancer varies by race/ethnicity: the Neighborhood and Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2014;23:793–811.
   PubMed Web of Science ®Google Scholar
• Lantz PM, Mujahid M, Schwartz K, et al. The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis. Am J Public Health. 2006;96:2173–2178.
   PubMed Web of Science ®Google Scholar
• Henry KA, McDonald K, Sherman R, et al. Association between individual and geographic factors and nonadherence to mammography screening guidelines. J Womens Health (Larchmt). 2014;23:664–674.
   PubMed Web of Science ®Google Scholar
• Adler NE, Newman K. Socioeconomic disparities in health: pathways and policies. Health Aff (Millwood). 2002;21:60–76.
   PubMed Web of Science ®Google Scholar
• Diez Roux AV. Investigating neighborhood and area effects on health. Am J Public Health. 2001;91:1783–1789.
   PubMed Web of Science ®Google Scholar
• Robert SA. Socioeconomic position and health: the independent contribution of community socioeconomic context. Annu Rev Sociol. 1999;25:489–516.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13–17 years – United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:685–693.
   PubMed Web of Science ®Google Scholar
• Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med. 2011;53(1):S29–S35.
   Web of Science ®Google Scholar
• Garland SM, Molesworth EG, Machalek DA, et al. How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect. 2015;21:834–841.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Liu B, Donovan B, et al. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine. 2014;32:592–597.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–966.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206:1645–1651.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Chow EP, Garland SM, et al. Human papillomavirus prevalence in unvaccinated heterosexual men after a national female vaccination program. J Infect Dis. 2017;215:202–208.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110:2804–2811.
   PubMed Web of Science ®Google Scholar
• Public Health England. Human papillomavirus (HPV) vaccine coverage in England, 2008/09 to 2013/14. A review of the full six years of the three-dose schedule. London: Public Health England; 2015.
   Google Scholar
• ICO Information Centre on HPV and Cancer: human papillomavirus and related diseases report. Denmark: ICO Information Centre on HPV; 2016.
   Google Scholar
• Farmar AM, Love-Osborne K, Chichester K, et al. Achieving high adolescent HPV vaccination coverage. Pediatrics. 2016;138:e20152653.
   PubMed Web of Science ®Google Scholar
• Moss JL, McCarthy SH, Gilkey MB, et al. Application of the Carolina framework for cervical cancer prevention. Gynecol Oncol. 2014;132:S33–S40.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968.
   PubMed Web of Science ®Google Scholar
• Denslow SA, Knop G, Klaus C, et al. Burden of invasive cervical cancer in North Carolina. Prev Med. 2012;54:270–276.
   PubMed Web of Science ®Google Scholar
• Downs LS, Smith JS, Scarinci I, et al. The disparity of cervical cancer in diverse populations. Gynecol Oncol. 2008;109:S22–S30.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• McCarthy AM, Dumanovsky T, Visvanathan K, et al. Racial/ethnic and socioeconomic disparities in mortality among women diagnosed with cervical cancer in New York City, 1995–2006. Cancer Causes Control. 2010;21:1645–1655.
   PubMed Web of Science ®Google Scholar
• Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93.
   PubMed Web of Science ®Google Scholar
• Singh GK, Miller BA, Hankey BF, et al. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975–2000. Cancer. 2004;101:1051–1057.
   PubMed Web of Science ®Google Scholar
• Pierce Campbell CM, Menezes LJ, Paskett ED, et al. Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiol Biomarkers Prev. 2012;21:1402–1408.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Cancer death rates–Appalachia, 1994–1998. MMWR Morb Mortal Wkly Rep. 2002;51:527–529.
   PubMedGoogle Scholar
• Binagwaho A, Wagner CM, Gatera M, et al. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. Bull World Health Organ. 2012;90:623–628.
   PubMed Web of Science ®Google Scholar
• Torres-Rueda S, Rulisa S, Burchett HE, et al. HPV vaccine introduction in Rwanda: impacts on the broader health system. Sex Reprod Healthc. 2016;7:46–51.
   PubMed Web of Science ®Google Scholar
• Binagwaho A, Ngabo F, Wagner CM, et al. Integration of comprehensive women’s health programmes into health systems: cervical cancer prevention, care and control in Rwanda. Bull World Health Organ. 2013;91:697–703.
   PubMed Web of Science ®Google Scholar
• Hutubessy R, Levin A, Wang S, et al. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO cervical cancer prevention and control costing tool. BMC Med. 2012;10:136.
   PubMed Web of Science ®Google Scholar
• Ladner J, Besson MH, Hampshire R, et al. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.
   PubMed Web of Science ®Google Scholar
• DiAngi YT, Panozzo CA, Ramogola-Masire D, et al. A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PLoS One. 2011;6:e25481.
   PubMed Web of Science ®Google Scholar
• Penny M, Bartolini R, Mosqueira NR, et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine. 2011;29:5022–5030.
   PubMed Web of Science ®Google Scholar
• Biellik R, Levin C, Mugisha E, et al. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine. 2009;27:6203–6209.
   PubMed Web of Science ®Google Scholar
• Opel DJ, Heritage J, Taylor JA, et al. The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics. 2013;132:1037–1046.
   PubMed Web of Science ®Google Scholar
• Benin AL, Wisler-Scher DJ, Colson E, et al. Qualitative analysis of mothers’ decision-making about vaccines for infants: the importance of trust. Pediatrics. 2006;117:1532–1541.
   PubMed Web of Science ®Google Scholar
• Fredrickson DD, Davis TC, Arnould CL, et al. Childhood immunization refusal: provider and parent perceptions. Fam Med. 2004;36:431–439.
   PubMed Web of Science ®Google Scholar
• Vadaparampil ST, Kahn JA, Salmon D, et al. Missed clinical opportunities: provider recommendations for HPV vaccination for 11–12 year old girls are limited. Vaccine. 2011;29:8634–8641.
   PubMed Web of Science ®Google Scholar
• Evans G, Bostrom A. The evolution of vaccine risk communication in the United States: 1982–2002. National Institute of allergy and infectious diseases. Jordan Report 20th anniversary: Accelerated development of vaccines; 2002:58–71.
   Google Scholar
• Esposito S, Bosis S, Pelucchi C, et al. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine. 2007;25:6437–6446.
   PubMed Web of Science ®Google Scholar
• Schnatz PF, Humphrey K, O’Sullivan DM. Assessment of the perceptions and administration of the human papillomavirus vaccine. J Low Genit Tract Dis. 2010;14:103–107.
   PubMed Web of Science ®Google Scholar
• Stewart A. Childhood vaccine and school entry laws: the case of HPV vaccine. Public Health Rep. 2008;123:801–803.
   PubMed Web of Science ®Google Scholar
• Reiter PL, McRee AL, Kadis JA, et al. HPV vaccine and adolescent males. Vaccine. 2011;29:5595–5602.
   PubMed Web of Science ®Google Scholar
• Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers-United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65:661–666.
   PubMed Web of Science ®Google Scholar
• Mourad M, Jetmore T, Jategaonkar AA, et al. Epidemiological trends of head and neck cancer in the United States: a SEER Population Study. J Oral Maxillofac Surg. 2017;75:2562–2572.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Chang M, Resto VA, et al. Prevalence of oral human papillomavirus by vaccination status among young adults (18–30years old). Vaccine. 2017;35:3446–3451.
   PubMed Web of Science ®Google Scholar
• Sonawane K, Suk R, Chiao EY, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167:714–724.
   PubMed Web of Science ®Google Scholar
• Whitney SN, McGuire AL, McCullough LB. A typology of shared decision making, informed consent, and simple consent. Ann Intern Med. 2004;140:54–59.
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24:S16–S22.
   PubMed Web of Science ®Google Scholar
• Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793–1802.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931–4939.
   PubMed Web of Science ®Google Scholar
• Kharbanda EO, Stockwell MS, Colgrove J, et al. Changes in Tdap and MCV4 vaccine coverage following enactment of a statewide requirement of Tdap vaccination for entry into sixth grade. Am J Public Health. 2010;100:1635–1640.
   PubMed Web of Science ®Google Scholar
• Brewer NT, Gottlieb SL, Reiter PL, et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis. 2011;38:197–204.
   PubMed Web of Science ®Google Scholar
• Rand CM, Szilagyi PG, Albertin C, et al. Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: a national study. Pediatrics. 2007; 120:461–466.
   PubMed Web of Science ®Google Scholar
• Woodwell DA, Cherry DK. National ambulatory medical care survey: 2002 summary. Adv Data. 2004;346:1–44.
   PubMedGoogle Scholar
• Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J. 2005;24:S134–S140.
   PubMed Web of Science ®Google Scholar
• Suh CA, Saville A, Daley MF, et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics. 2012;129:e1437–e1445.
   PubMed Web of Science ®Google Scholar
• Kontos EZ, Emmons KM, Puleo E, et al. Contribution of communication inequalities to disparities in human papillomavirus vaccine awareness and knowledge. Am J Public Health. 2012;102:1911–1920.
   PubMed Web of Science ®Google Scholar